J.C. Eymard

Doxorubicin and Ifosfamide in Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: A Phase II Study of the Genitourinary Group of the French Federation of Cancer Centers

Bernard Escudier, Jean‐Pierre Droz, Frédéric Rolland et al. · The Journal of Urology · 2002 · 78 citations

Medicine, Oncology, Pharmacology +16

Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers.

Bernard Escudier, Jean‐Pierre Droz, Frédéric Rolland et al. · PubMed · 2002 · 73 citations

Medicine, Oncology, Pharmacology +17

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab

Jean‐Yves Pierga, François‐Clément Bidard, A Autret et al. · Annals of Oncology · 2016 · 72 citations · Full text

Medicine, Oncology, Breast Oncology +13

Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?

Renaud Sabatier, J.C. Eymard, Jochen Walz et al. · Annals of Oncology · 2011 · 69 citations · Full text

Medicine, Oncology, Pharmacology +13

Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial

C. Sternberg, Daniel P. Petrylak, Fred Witjes et al. · Journal of Clinical Oncology · 2007 · 62 citations

Medicine, Oncology, Pharmacology +8